You are not authorised to view this resource.
You need to login.
You need to login.
At this instant
- Aprea strengthens its board, December 22
- Aprea announces continuation of Phase I/II-study of APR-246 in patients with leukemia, December 12
- Åsa Fransson, new Scientist at Aprea AB, December 12
- Aprea secures funding for further development of the anticancer compound APR-246, September 9
- Aprea reports completion of the Phase I/II safety study with APR-246 in cancer patients, February 23